Prevalence of Gestational Diabetes in Metformin-treated and Non-Treated PCOS Women: A Comparative Analysis
Abstract
Polycystic Ovary Syndrome (PCOS) is one of the most prevalent endocrinal disorders in the reproductive age of women and is, therefore, a risk
factor for Gestational Diabetes Mellitus (GDM). One of the medications used in the management of PCOS is metformin and its use has been
proposed to decrease the occurrence of GDM. The purpose of this study focuses on the effects of the dose and duration of metformin treatment on
the prevalence of GDM among pregnant women affected by PCOS.
A cross-sectional survey was carried out on 112 pregnant women diagnosed with PCOS in tertiary care hospitals in Karachi. Data were collected
through a structured questionnaire, in which 55 patients received metformin and others did not receive metformin. Both groups were compared for
the prevalence of GDM. Chi-square test was used in data analysis at a significance level of p < 0. 05.
GDM was found to be significantly higher in non-metformin group than metformin group (60% vs 40%, P=0.03). The data analysis extended this
finding, which concluded that metformin use is inversely related to GDM risk (p = 0.02).
This study shows that metformin therapy reduces the incidence of GDM in pregnant PCOS patients and may be used to prevent GDM in such
patients. Such outcomes indicate the possibility of the use of metformin as a means of preventing GDM in this group of patients.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.